View Post

New ASCO Studies Offer Evidence for Use of Circulating Tumor Cells as a Prognostic Biomarker for Advanced Prostate and Breast Cancer

In Clinical Studies News by Barbara Jacoby

Results from prospective trials show a “clear prognostic value” for CTC counts Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology (ASCO) suggest that circulating tumor cell (CTC) counts may be useful in determining long-term prognosis …